AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
Statement of unaudited financial results for the quarter and nine months ended 31 December 2021

'Rs in lakhs except for earnings per share data

Sl No.	Particulars	3 months ended 31/12/2021	Previous 3 months ended 30/09/2021	Corresponding 3 months ended in the previous year 31/12/2020	9 months ended 31/12/2021	9 months ended 31/12/2020	Year ended 31/03/2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Income**						
	a) Revenue from operations	20,052.72	19,770.76	20,025.20	57,363.68	60,330.67	81,356.38
	b) Other income	533.06	284.33	292.82	1,107.37	1,028.88	1,284.14
	Total income	**20,585.78**	**20,055.09**	**20,318.02**	**58,471.05**	**61,359.55**	**82,640.52**
2	**Expenses**						
	(a) Cost of materials consumed	2,657.74	2,263.38	2,619.86	6,689.07	7,102.92	9,725.78
	(b) Purchase of stock-in-trade	3,861.97	7,441.66	2,135.03	14,609.51	13,775.75	19,474.22
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,245.99	(1,679.27)	2,075.59	1,139.70	963.11	294.59
	(d) Employee benefits expense	5,906.28	5,788.69	5,505.53	17,174.31	16,704.75	21,954.39
	(e) Depreciation expense	350.55	427.57	511.04	1,254.20	1,429.40	2,012.59
	(f) Allowance for expected credit loss (net)	85.68	80.26	21.37	295.19	190.43	271.90
	(g) Selling, marketing and distribution expense	1,445.73	983.80	1,432.89	3,457.98	3,505.54	4,520.68
	(h) Other expenses	3,382.65	3,100.60	3,160.58	9,176.51	8,581.01	11,567.69
	(i) Finance costs	22.73	24.69	26.04	74.01	81.12	109.30
	Total expenses	**18,959.32**	**18,431.38**	**17,487.93**	**53,870.48**	**52,334.03**	**69,931.14**
3	**Profit before exceptional and extraordinary items and tax (1-2)**	**1,626.46**	**1,623.71**	**2,830.09**	**4,600.57**	**9,025.52**	**12,709.38**
4	Exceptional items	-	-	-	-	-	-
5	**Profit before extraordinary items and tax (3+4)**	**1,626.46**	**1,623.71**	**2,830.09**	**4,600.57**	**9,025.52**	**12,709.38**
6	Extraordinary items	-	-	-	-	-	-
7	**Profit before tax (5+6)**	**1,626.46**	**1,623.71**	**2,830.09**	**4,600.57**	**9,025.52**	**12,709.38**
8	**Tax expense**						
	- Current tax	447.64	477.22	773.62	1,341.51	2,627.91	3,482.78
	- Deferred tax charge / (credit)	36.90	(48.21)	(48.69)	(101.89)	(204.85)	(103.75)
	Total tax expense	**484.54**	**429.01**	**724.93**	**1,239.62**	**2,423.06**	**3,379.03**
9	**Profit after tax (7-8)**	**1,141.92**	**1,194.70**	**2,105.16**	**3,360.95**	**6,602.46**	**9,330.35**
10	**Other comprehensive income/(loss)**						
	A. Items that will not be reclassified to profit or loss						
	Re-measurement gains/(losses) on post employment benefit obligations	(55.88)	(46.30)	(5.20)	(114.50)	88.71	457.96
	Income tax effect on above	14.07	11.65	1.31	28.82	(22.33)	(115.26)
	Total other comprehensive income/ (loss), net of income tax	**(41.81)**	**(34.65)**	**(3.89)**	**(85.68)**	**66.38**	**342.70**
	Total comprehensive income for the period (9+10)	**1,100.11**	**1,160.05**	**2,101.27**	**3,275.27**	**6,668.84**	**9,673.05**
11	**Paid-up equity share capital** (Face value of Rs 2/- per equity share)	**500.00**	**500.00**	**500.00**	**500.00**	**500.00**	**500.00**
12	Reserves (excluding revaluation reserves as per balance sheet)	-	-	-	-	-	45,117.28
13	**Earnings per equity share of Rs 2/- each (basic and diluted)**	**4.57**	**4.78**	**8.42**	**13.44**	**26.41**	**37.32**

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Statement of unaudited financial results for the quarter and nine months ended 31 December 2021

Notes:

1 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.

3 The Company has not experienced any significant impact on its operations, recoverability of carrying amounts of financial and non-financial assets and liquidity due to current wave of COVID 19 pandemic. As the pandemic continues to evolve, the Company will continue to closely monitor any material changes to future economic conditions.

4 During the June'21 quarter, the Company received a demand notice for an amount of Rs.15,738.85 lakhs (and interest thereupon) under Trade Margin Rationalisation notification ("TMR notification") from National Pharmaceutical Pricing Authority (NPPA) alleging overcharging of a patented anti-cancer drug sold during the period of 8 March 2019 to 31 January 2021. The said drug has been included with certain other anti-cancer medicines, on which trade margin caps are applicable under TMR notification.
Based on evaluation, Management is of the view that the TMR notification is not applicable to the aforesaid patented drug and all applicable laws relating to the pricing of the product have been complied with. The Company has filed a Writ Petition before the High Court of Delhi challenging the NPPA's demand notice and the matter is pending adjudication. Based on assessment, supported by external legal advice, Management has concluded that it has a strong case and the Company can defend its position. Accordingly, no provision has been made in these financial results.

5 Previous period's figures have been regrouped/reclassified, where necessary, to conform with the current period's presentation for the purpose of comparability.

6 This statement of finanacial results was reviewed and recommended by the Audit Commiltee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 08 February 2022. The Statutory auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 31 December 2021.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

GAGANDEEP SINGH BEDI
Digitally signed by GAGANDEEP SINGH BEDI
Date: 2022.02.08 17:44:14 +05'30'

Place: Bengaluru
Date: 08 February, 2022

Gagandeep Singh Bedi
Managing Director